Goldman Sachs added Vertex Pharmaceuticals to its U.S. conviction buy list and RWE and Adyen to its European conviction list as of September 1, 2026, according to the firm's monthly refresh of its highest-conviction stock recommendations.
Conviction lists are Goldman Sachs' tier-one equity recommendations, typically comprising 25 to 30 names per region. The firm updates them monthly and weights them more heavily than its standard buy ratings in client portfolios. Names on conviction lists represent positions Goldman's equity research team believes have the highest near-term total return potential relative to their risk.
Vertex, a Cambridge-based biotechnology company with a market capitalization near $50 billion, develops therapies for cystic fibrosis, sickle cell disease, and other serious conditions. RWE, the German power and renewable energy operator valued around $40 billion, has been repositioning its portfolio toward wind and solar generation. Adyen, the Dutch payments processor with a market value near $75 billion, processes digital transactions for merchants and platforms globally.
Goldman's conviction list reaches allocators managing trillions in assets. Inclusion on a conviction list can factor into index fund tracking decisions and systematic mandate construction. The refresh comes as equity markets weigh earnings growth, interest rate paths, and macroeconomic conditions heading into the final quarter of the year.
Goldman's September refresh marks the monthly rotation typical of the conviction process, though the firm does not disclose which names were removed to make room for these three additions. Conviction lists are not static; they turn over regularly as market conditions, company fundamentals, and valuation inflection points shift.
Three additions across two geographic mandates in a single month is a routine occurrence in the conviction rebalancing cycle rather than an anomaly. The three companies span separate sectors, pharmaceuticals, utilities, and fintech payments, reflecting broad conviction coverage rather than concentration in one thesis. If Goldman Sachs' research team has identified material forward catalyst acceleration for any of these names, the firm would typically flag that reasoning in accompanying equity reports or client notes accompanying the conviction list refresh.
